Pharma Dodges Senate Bullet, Roche Pays $4.8B for Spark, & BMS-Celgene Deal Wobbles

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

Roche/Genentech’s Clever NTRK Strategy, Regeneron’s Ebola Win & PCR Pioneer Passes
Novartis’ No-No, Bayer Buys BlueRock, and Job Switches Galore
BioNTech Snags $320m, Roche/Spark Delay, & Summer Job Switches
AbbVie & Allergan (Groan), Adaptive Headlines IPO Rush, & FDA Cops on the Beat